AzTrials
AzTrials

Iliotibial Band SyndromeNCT06867159

Autogenic Inhibition Versus Reciprocal Inhibition Muscle Energy Techniques in Iliotibial Band Syndrome

A study testing Autogenic Inhibition (AI) MET (Post Facilitation Stretch) and Reciprocal Inhibition (RI) MET in people with Iliotibial Band Syndrome, run by Foundation University Islamabad at 1 site in Pakistan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Comparison of effects of autogenic inhibition and reciprocal inhibition muscle energy techniques on iliotibial band syndrome Read more about this study

Who is it for?
Ages 19 to 45 years
Conditions the study is for
Iliotibial Band Syndrome
What is being tested?
Autogenic Inhibition (AI) MET (Post Facilitation Stretch) and Reciprocal Inhibition (RI) MET
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 sitePakistan
Study dates
15 Jul 2024to 15 Jul 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Both male and female participants
  • Age : 19-45years (8)
  • Lateral knee pain (>3 months)
  • Tenderness over lateral femoral condyle
  • Positive Flexibility Tests
  • Modified Ober's test (9)
Show all 10Show fewer
  • Length assessment of Tensor Fasciae Latae and Iliotibial Band (10)
  • Positive Pain Provocation Tests
  • Renne's test
  • Noble's Compression test (11) *(individuals with 3 positive tests out of above mentioned 4 tests will be included)

Who cannot join

  • Recent lower limb or pelvic girdle surgery within the past 3 months
  • Lower limb fractures or trauma within the past year.
  • Multiple lower limb surgeries (>2)
  • Presence of any structural or postural disorders (kyphosis or severe scoliosis)
  • Neurological disorders
  • Hip and knee Osteoarthritis
  • Rheumatoid Arthritis
  • Pregnancy

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Rida Ishtiaq, MS-MSKPT* contact

03365530415

ridaishtiaq777@gmail.com

Pakistan1 site, 1 recruiting
  • Foundation University College of Physcial Therapy

    Rawalpindi, Punjab Province, 46000

    Furqan Yaqoob, OMPT,PHD*, 03465333101, furqan.yaqoob@fui.edu.pk

    Recruiting

Other trials in Pakistan

About this study

Official title: Comparison of Effects of Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques on Iliotibial Band Syndrome

Comparison of effects of autogenic inhibition and reciprocal inhibition muscle energy techniques on iliotibial band syndrome

Read the detailed description

A single-blinded randomized control trial will be conducted over a period of one year in Foundation University Islamabad. Forty participants will be assigned to two groups: Group A (AI) and Group B (RI), with 20 participants each. The AI technique will involve a maximal isometric contraction of the target muscle followed by a stretch, while the RI technique will involve a maximal isometric contraction of the antagonist muscle followed by a similar stretching protocol. Both groups will perform the exercises 3 times per week for 2 weeks. Pain, Hip range of motion (ROM) and lower extremity function will be assessed using Numeric Pain Rating Scale (NPRS), goniometer and Lower Extremity Functional Scale (LEFS) respectively.

The outcomes will be measured in terms of improvements in pain score (NPRS), hip range of motion (ROM), and overall lower extremity function.

Being tested
Autogenic Inhibition (AI) MET (Post Facilitation Stretch), Reciprocal Inhibition (RI) MET
Medical subject headings
Iliotibial Band Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Autogenic Inhibition (AI) MET (Post Facilitation Stretch)Procedure or surgery

    Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

    1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
    2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
    3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
    4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.
  • Reciprocal Inhibition (RI) METProcedure or surgery

    Reciprocal Inhibition (RI) MET

    1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
    2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
    3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
    4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.
Study groups in NCT06867159
Study groupRoleWhat they receive
Autogenic Inhibition (AI) MET GroupExperimentalAutogenic Inhibition (AI) MET (Post Facilitation Stretch) 1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state. 2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely. 3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds. 4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.
Receives: Procedure: Autogenic Inhibition (AI) MET (Post Facilitation Stretch)
Reciprocal Inhibition (RI) MET GroupExperimentalReciprocal Inhibition (RI) MET 1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state. 2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely. 3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds. 4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.
Receives: Procedure: Reciprocal Inhibition (RI) MET

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain severity

    Pain will be assessed using Numeric Pain Rating Scale (NPRS),

    Measured: 2 weeks

  2. Range of motion

    Hip range of motion (ROM) will be assessed using goniometer

    Measured: 2 weeks

  3. Functional status of lower limb

    Lower extremity function will be assessed using Lower Extremity Functional Scale (LEFS)

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Mar 2025
  2. Study start15 Jul 2024
  3. Primary completion15 Jun 2025 (estimated)
  4. Study completion15 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Controlled Trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06867159
Sponsor's protocol ID
FUI/CTR/2025/3
Status last verified
Mar 2025
First submitted
4 Mar 2025
Last updated
10 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Autogenic Inhibition (AI) MET (Post Facilitation Stretch) and Reciprocal Inhibition (RI) MET in people with Iliotibial Band Syndrome, run by Foundation University Islamabad at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 10 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rida Ishtiaq, MS-MSKPT* (03365530415, ridaishtiaq777@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain severity (time frame: 2 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in